AzTrials
AzTrials

Essential TremorPhase 2NCT07103265

Developing a New LIFU Neuromodulation Method to Suppress Tremor

A Phase 2 study testing Transcranial focused ultrasound stimulation in people with Essential Tremor, run by University of Calgary.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

The investigators aim to apply low intensity focused ultrasound neuromodulation to patients with essential tremor to evaluate the efficacy of this intervention in reducing the amplitude of hand tremor compared to sham stimulation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Essential Tremor
What is being tested?
Transcranial focused ultrasound stimulation
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
20 participants
Where
No sites listed yet
Study dates
15 Sep 2025to 15 Jul 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of Essential Tremor OR Diagnosis of Parkinson's Disease

Who cannot join

  • Presence of any neurological diagnosis other than Essential Tremor and Parkinson's Disease
  • Family history of Essential Tremor OR Parkinson's Disease
  • Inability to undergo MRI or attend to the experimental study sessions

About this study

Official title: Developing a New Low-intensity Focused Ultrasound (LIFU) Neuromodulation Method to Suppress Tremor

The investigators aim to apply low intensity focused ultrasound neuromodulation to patients with essential tremor to evaluate the efficacy of this intervention in reducing the amplitude of hand tremor compared to sham stimulation.

Read the detailed description

Transcranial ultrasound stimulation is a non-invasive brain stimulation that uses low intensity focused ultrasound (LIFU) to modulate neural activity with high spatial precision (Zadeh et al., 2024). Several human and animal studies have demonstrated that LIFU can produce lasting neuromodulatory effects, including both excitatory and inhibitory responses in the primary motor cortex (Zadeh et al., 2024). Furthermore, evidence suggests that LIFU is capable of inducing plasticity in the human brain that resembles long term potentiation or long-term depression (Zeng et al., 2024). The ability of LIFU to induce bidirectional effects, either excitatory or inhibitory, depending on sonication parameters, offers a level of flexibility in tailoring neuromodulatory interventions to individual patient needs and specific neural circuit dysfunctions. Combined with real-time neuronavigation and acoustic modeling tools, LIFU provides a promising platform for precise, personalized, and non-invasive brain stimulation. The modulatory effect of LIFU depends on sonication parameters such as frequency, attenuation, and pulse repetition frequency (Zeng et al., 2024; Manuel et al., 2020), and evidence from both preclinical and clinical studies suggests these effects can persist beyond the stimulation period consistent with long-term potentiation or long-term depression-like plasticity mechanisms (Fomenko et al., 2020; Zadeh et al., 2024).

Unlike other neuromodulatory techniques such as transcranial magnetic stimulation and transcranial direct current stimulation, LIFU offers the unique capability to reach deep brain structures while maintaining a focal spatial resolution. This advantage of precise targeting of deep brain regions such as the thalamus without the need for surgical intervention make LIFU a highly useful modality for investigating disorders (Legon et al., 2018). Structures like the ventral intermediate nucleus (Vim) of the thalamus, commonly implicated in movement disorders such as essential tremor and Parkinson's disease, can be non-invasively stimulated using LIFU to modulate aberrant neural activity.

In a previous study, we piloted an ultrasound transducer integrated with standard optical tracking-based neuro-navigation to establish a safety and tolerability benchmark for LIFU to reduce tremor in patients with Essential Tremor or Parkinson's disease, while also optimizing stimulation parameters prior to broader clinical application. Our open label study, currently under review for publication, demonstrated high efficacy and safety of our system to transiently reduce, in the short term, tremor amplitude measured using accelerometric recordings. By integrating rigorous screening, controlled stimulation parameters, and standardized monitoring protocols, we propose here a randomized sham-controlled study to advance knowledge on efficacy and safety of this technology in a larger clinical sample of patients with these diagnoses. As LIFU continues to expand into therapeutic realms, such foundational research will be essential for supporting its evidence-based integration into neuroscience and medicine.

Objectives. AIM: To determine if we can low intensity focused ultrasound (LIFU, a neuromodulatory form of ultrasound) in the laboratory setting can transiently suppress tremor when targeting motor thalamus in patients with tremor.

HYPOTHESIS: Specific LIFU patterns applied to deep thalamic targets will transiently induce reduce tremor in patients with tremor.

IMPACT: If successful, we could use LIFU to help predict potential efficacy of permanent lesioning on tremor as well as support further investigation of LIFU as a novel non-invasive neuromodulation strategy for tremor.

Being tested
Transcranial focused ultrasound stimulation, Sham stimulation
Medical subject headings
Essential Tremor

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcranial focused ultrasound stimulationDevice

    Parameters Range of values Fundamental frequency 250 kHz Transducer diameter 15 cm Focal distance 13.5 cm (steerable +/- 5-10 mm from the center) Pulse repetition frequency 100 Hz Duty cycle 10% Duration 2 min for each of the 7 foci Peak spatial intensity (Isppa) 10.0 W/cm2 Peak temporal average intensity (Ispta) 1.2 W/cm2 Mechanical index (MI) 0.48 * Thermal index (TI) 0.8oC **

  • Sham stimulationDevice

    Same set-up as for real stimulation but with without delivering any ultrasound stimulation

Study groups in NCT07103265
Study groupRoleWhat they receive
Real stimulationExperimentalWe use an in-house developed focused ultrasound system that uses a 128-element phased array transducer (diameter of 135 mm, F#=0.8) operating at 700 kHz and mounted on a specialized arm for stereotactic neuronavigation. It has been tested in normal subjects targeting cortical structures (REB#19-1614, #21-0959), and in thalamus for the pilot data collection for this project (REB#22-1437). Patients will be seated comfortably in a chair equipped with neuronavigation (BrainSight, Rogue) positioning the custom LIFU array. The LIFU array will be applied to the scalp, with hair parted and ultrasound gel applied, and held in place using the neuronavigation arm.
Receives: Device: Transcranial focused ultrasound stimulation
Sham stimulationSham comparatorSame setting as Real stimulation, but without delivering any ultrasound stimulation.
Receives: Device: Sham stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in power spectral density (PSD) of tremor accelerometric trace between post-sonication (Round 1) and baseline

    This outcome will be measured using triaxial accelerometry performed on the participants' index finger (treated side). Accelerometry will be analyzed by summing traces from each axis, after using Welch's method to calculate the power spectral density (PSD), with 3-7 Hz tremor frequency range selected for the area under the curve and transformed into logarithmic scale to account for the variability in tremor amplitude at baseline. The primary endpoint will be the percent change in PSD between the post-sonication recording after the 1st Round of the session and the baseline recording.

    Measured: 5 minutes

Secondary outcomes (3)
  1. Change in power spectral density (PSD) of tremor accelerometric trace between post-sonication (Round 2) and baseline

    This outcome will be measured using triaxial accelerometry performed on the participants' index finger (treated side). Accelerometry will be analyzed by summing traces from each axis, after using Welch's method to calculate the power spectral density (PSD), with 3-7 Hz tremor frequency range selected for the area under the curve and transformed into logarithmic scale to account for the variability in tremor amplitude at baseline. The primary endpoint will be the percent change in PSD between the post-sonication recording after the 2nd Round of the session and the baseline recording.

    Measured: 5 minutes

  2. Change in Clinical Rating Scale for Tremor sub-score corresponding to the sum of scale items related to the treated side between the post-sonication rating and the baseline rating (participants with ET)

    This applies only to participants with a diagnosis of Essential Tremor

    Measured: 5 minutes

  3. Change in the Movement Disorders Society-Unified Parkinson's Disease Rating Scale sub-score corresponding to the sum of resting tremor items of the scale between the post-sonication rating and the baseline rating (participants with PD).

    This applies only to participants with a diagnosis of Parkinson's disease

    Measured: 5 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2025
  2. Study start15 Sep 2025 (estimated)
  3. Primary completion15 Jul 2027 (estimated)
  4. Study completion15 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
We use an in-house developed focused ultrasound system that uses a 128-element phased array transducer (diameter of 135 mm, F#=0.8) operating at 700 kHz and mounted on a specialized arm for stereotactic neuronavigation. Patients will be seated comfortably in a chair equipped with neuronavigation (BrainSight, Rogue) positioning the custom transcranial ultrasound (TUS) array. The TUS array will be applied to the scalp, with ultrasound gel applied, and held in place using the neuronavigation arm. The control session will have the same duration of the real stimulation session, i.e., it will be divided in two 40-minutes long rounds. During the first round, participants will receive sham stimulation which is unfocused, thereby providing the same sound but without sufficient intensity at any location. After the break, during the second round participants will receive TUS stimulation at the same energy parameters as in the real stimulation session but positioning the focus in the CSF space.
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07103265
Sponsor's protocol ID
REB22-1437
Status last verified
Jun 2025
First submitted
2 Jul 2025
Last updated
5 Aug 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Transcranial focused ultrasound stimulation in people with Essential Tremor, run by University of Calgary.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in power spectral density (PSD) of tremor accelerometric trace between post-sonication (Round 1) and baseline (time frame: 5 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in